|
nombre  pulsa para comparar los precios |
Afrin | Bain de Soleil | Canji, Chlor-Trimeton, Clarinex, Claritin, Clarityne, Coppertone, Correctol | Drixoral | Intron A | Lotrimil | Nasonex, NeoGenesis Pharmaceuticals | Organon Biosciences | Proventil | Ralgro, Remicade | Schering-Plough , Scholl (licence in the United States), Solarcaine | Tinactin | Vancenase, Vanceril |
Compremos local, �tica y al mejor precio sobre Ethishop  |
|
|
|
a�o | actividad fuente |
2006 | Schering Plough es el decimosexto grupo farmac�utico mundial. | Les Echos |
|
pa�s | direcci�n & contacto : tipo de producci�n incentivo fuente |
Bermuda | Garden Insurance Co., Ltd : |
Bermuda | Schering-Plough China, Ltd : |
Hong-Kong | Schering-Plough Animal Health Ltd : |
Irlanda | Loftus Bryan Chemicals Ltd : |
Irlanda | Mallinckrodt Veterinary Ltd : |
Irlanda | Schering-Plough Pensions Ireland Ltd : |
Irlanda | Avondale Chemical Co., Ltd : |
Irlanda | Chemibiotic (Ireland) Ltd : |
Mexico | DISTRITO FEDERAL XOCHIMILCO 16 DE SEPTIEMBRE 301 XALTOCAN & 015 7284444 : Sistema de Informacion de la Industria Maquiladora |
Panam� | Colombia Veterinary Holdings, Inc : |
Filipinas | Plough Consumer Products (Philippines) Inc : |
Filipinas | Schering-Plough Animal Health, Inc : |
Singapur | 2 usines : Zetia, Peg-Intron, Remicade Les Echos |
Singapur | Schering-Plough Animal-Health Pte. Ltd : |
Suiza | Werthenstein Chemie A.G : |
Suiza | Trading Pharma AG : |
Suiza | Schering-Plough Ltd : |
Suiza | Plough Services AG : |
Suiza | Schering-Plough Central East A.G : |
Suiza | Giralda Investments Ltd : |
|
a�o nombre | foto posici�n; remuneraci�n fuente |
2002Connors, Joseph |  Pr�sident du Conseil; salario: 1,58 milliones US$; stock-options: 0,95 milliones US$;
|
|
a�o | empleados <> | impacto social : pa�s fuente |
2008 | -330 | Fusi�n/Adquisici�n: Schering Plow reorganiz� su fuerza de ventas tras la adquisici�n de Organon laboratorio.: Francia | Les Echos |
2008 | -1000 | Reestructuraci�n interna: Schering Plough lanza un plan d' ahorro de 1,5 mil millones de d�lares debido a la reducci�n de las ventas de sus anticholesterol Vytorin y Zetia y suprime puestos de comerciales.: Estados Unidos | Les Echos |
2006 | -1100 | Reestructuraci�n interna: Schering-Plough will streamline or phase out operations at its manufacturing facilities in Puerto Rico and New Jersey. The plan will cost $250 million and save the company $100 million a year. traducir : Estados Unidos | Reuters |
2004 | -170 | | The Irish Examiner |
2003 | -900 | Reestructuraci�n interna: | AP |
1989 | -105 | | Canadian Labour Congress |
|
a�o | empleados <> | impacto social : pa�s fuente |
|
a�o | pa�s : consecuencias fuente |
|
a�o | pa�s : consecuencias fuente |
|
a�o | delincuencia financiera | ventas | resultado | | | fuente |
2008 |
| 18,5 | 1,79 | | | mil milliones US$ | |
2007 |
| 10,59 | -1,59 | | | mil milliones US$ | |
2006 |
| 10,6 | 1,06 | | | mil milliones Eu� | Les Echos |
2005 |
| | 0,18 | | | mil milliones US$ | |
2005 |
Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said. Shering-Plough settles the case for 435 million dollars. traducir |
| | | | | | Bloomberg |
2004 |
| | -0,9 | | | mil milliones US$ | Les Echos |
2003 |
| 8,33 | -0,09 | | | mil milliones US$ | |
2002 |
| 10,18 | 1,97 | | | mil milliones US$ | |
2002 |
Allegedly sold misbranded medicines, submitted false pricing data or offered free samples to lure customers traducir |
| | | | | | Bloomberg |
2001 |
| 9,8 | 1,94 | | | mil milliones US$ | |
2000 |
| 9,82 | 2,42 | | | mil milliones US$ | |
1999 |
| 9,18 | 2,11 | | | mil milliones US$ | |
1998 |
| 8,08 | 1,76 | | | mil milliones US$ | |
|
a�o | delincuencia financiera | ventas | resultado | activo | recompra | fuente |
|
a�o | objectivo : intermediario/lobby : instituci�n fuente |
2001 | : USCIB (US Council For International Business) : : US Government traducir | USCIB |
2000 | Lobbying sobre las autoridades Estados-uniennes para prolongar tres a�os la explotaci�n exclusiva de su antiallergique Clarityne - 2 mil millones de d�lares de beneficios al a�o -, de los cuales los derechos expiran en 2002. La p�ldora gen�rica costar�a un mediod�lar, mientras que actualmente el producto se vende 2,50 d�lares. : importe: 4300 mil US$ traducir | Le Monde Diplomatique |
2000 | : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate traducir | Washington Post |
2000 | : EFPIA (European Federation of Pharmaceutical Industry Associations) : : European Commission traducir | EFPIA |
2000 | : FEDESA : : European Commission traducir | Fedesa |
1998 | : Contribution to Candidate's Political Action Committee : importe: 170 mil US$ : US President, Congress, Senate traducir | Center for Responsive Politics |
1997 | : Direct donation : importe: 265 mil US$ : US President, Congress, Senate traducir | Center for Responsive Politics |
1997 | : Direct donation : importe: 2683 mil US$ : US President, Congress, Senate traducir | Center for Responsive Politics |
|
a�o | objectivo : intermediario/lobby : instituci�n fuente |
|
a�o | pr�ctica dudosa : imagen fuente |
2006 | Falsa publicidad: | AFP |
2002 | Desinformaci�n: relaciones publicas: P | CB-News |
2001 | presupuesto pub: 236 milliones US$; | Advertising Age |
2000 | presupuesto pub: 263 milliones US$; | Advertising Age |
|
|
|